Peptide receptor radionuclide therapy

By indication / Peptide receptor radionuclide therapy

2 imaging agents and 27 therapeutic agents reported for this indication. Stage reflects how far each has been taken, not what is available in any given country.

Imaging

Agent	Isotope	Stage	Syntheses
[68Ga]Ga-DOTATATE paired with [177Lu]Lu-DOTATATE	Ga-68	Approved	94
[64Cu]Cu-sartate paired with [67Cu]Cu-SARTATE	Cu-64	first-in-human	4

Therapy

Agent	Isotope	Stage	Syntheses
[177Lu]Lu-DOTATATE paired with [68Ga]Ga-DOTATATE	Lu-177	approved (FDA-approved)	77
[177Lu]Lu-DOTA-TOC paired with [68Ga]Ga-DOTA-TOC	Lu-177	—	28
[90Y]Y-DOTA-TOC paired with [68Ga]Ga-DOTA-TOC	Y-90	—	19
[177Lu]Lu-DOTA-MGS5	Lu-177	first therapeutic clinical trial initiation / first-in-patient therapy	10
[225Ac]Ac-DOTATATE paired with [68Ga]Ga-DOTATATE	Ac-225	Phase 1b/3 clinical trial	8
[177Lu]Lu-DOTA-LM3	Lu-177	first-in-human	8
[90Y]Y-DOTA-Phe1-Tyr3-octreotide	Y-90	Phase I/II	7
[212Pb]Pb-PSC-PEG2-TOC	Pb-212	—	6
[177Lu]Lu-DOTA-JR11	Lu-177	—	6
[177Lu]Lu-AMTG	Lu-177	first-in-human	5
[177Lu]Lu-oxodotreotide	Lu-177	—	5
[177Lu]Lu-CP04	Lu-177	—	4
[90Y]Y-DOTATATE paired with [68Ga]Ga-DOTATATE	Y-90	—	4
[161Tb]Tb-DOTATATE paired with [68Ga]Ga-DOTATATE	Tb-161	—	4
[177Lu]Lu-HA-DOTATATE	Lu-177	—	4
[161Tb]Tb-DOTA-LM3	Tb-161	Phase 0 clinical study	3
[212Pb]Pb-DOTAMTATE	Pb-212	preclinical	3
[90Y]Y-DOTA-DPhe1-Tyr3-octreotide	Y-90	—	2
[177Lu]Lu-DOTA-CCK-66 paired with [68Ga]Ga-DOTA-CCK-66	Lu-177	preclinical study	2
[161Tb]Tb-3p-C-NETA paired with [68Ga]Ga-3p-C-NETA	Tb-161	—	1
[161Tb]Tb-DOTA-TOC paired with [68Ga]Ga-DOTA-TOC	Tb-161	preclinical study	1
[225Ac]Ac-DOTA-LM3	Ac-225	first-in-human	1
[177Lu]Lu-EB-TATE	Lu-177	—	1
[90Y]Y-90-DOTATOC/DOTATATE	Y-90	—	1
[177Lu]Lu-LNC1010	Lu-177	first-in-human	1
[177Lu]Lu-DOTA-EB-TATE	Lu-177	—	1
[212Pb]Pb-DOTAM-GRPR1	Pb-212	preclinical study	1

Have a question?Reagents, modules, introductions to manufacturers or to specialists in your region — tell us what you need.

Get in touch